Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Novel therapies for children with severe asthma
Top Ten Searches
hla beta 2 probiotics hypo allergenic scid urticaria aeroallergens asthma angioedema hivYour Article Summary
See Latest Articles
Aerts NE et al. – In rheumatoid arthritis, adalimumab therapy decreases the phosphorylation of p38 MAPK except for its response to TNF/IL-1, while enhancing the production of IFN?, sugesting that p38 MAPK is not directly involved in the effect of TNF inhibition on cytokine production.
Methods- Phosphorylation of p38 MAPK was analysed flow cytometrically in peripheral blood mononuclear cells (PBMC) from healthy individuals and RA patients before and after adalimumab therapy
- Cytokine production by CD3/CD28-stimulated PBMC was measured in the supernatant
- Despite a transient activation of p38 MAPK in response to cellular stress from the cell separation, a significant decrease of spontaneous p38 MAPK phosphorylation was observed after adalimumab, compared to RA patients with active disease
- Brief stimulation with TNF?/IL-1? significantly activated p38 MAPK after but not before adalimumab therapy
- In CD3/CD28-stimulated PBMC, significantly less p38 MAPK activation and increased IFN? production were observed after adalimumab therapy
Related Articles
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09
Relevance Score: 71%
Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09
Relevance Score: 70%
Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 70%
Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09
Relevance Score: 69%
Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 69%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment
Journal of Allergy and Clinical Immunology, 11/25/09
Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
Journal of Allergy and Clinical Immunology, 11/25/09
High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations
Journal of Allergy and Clinical Immunology, 11/25/09
Today in Rheumatic/Autoimmune...keeping you current
Receive free subspecialty "5-minute updates" via email
Update in treatment options for psoriatic arthritis
Expert Review of Clinical Immunology, 11/23/09
Adalimumab for the treatment of psoriatic arthritis
Expert Review of Clinical Immunology, 11/19/09
Functional activation of proline-rich tyrosine kinase2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus
BMC Musculoskeletal Disorders, 11/18/09
Sponsor
Article Search
Sponsor